Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients

Inclusion Criteria: * Aged 18 years old or more; * Late stage NSCLC patients, with tumor invasion confirmed by histopathology analysis. Metastasis of axillary lymph nodes and other region lymph nodes are confirmed with histopathologic or cytopathologic analysis; * Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumor; * No clinical evidence of other malignancy, unstable complication or uncontrolled infection; * Life expectancy \> 12 months. * Informed and signed consent by the patient. Exclusion Criteria: * Not accessible to biopsy and/or surgery sample; * Patient already enrolled in another clinical trial with another first line of chemotherapy; * Unmeasurable locally advanced (incurable) or metastatic lesion(s), according to RECIST 1.1 criteria; * Women who are pregnant, plan to become pregnant or are lactating during the study; * Elevation of carcinoembryonic antigen (CEA) observed without distal metastases found; * Have some kind of contraindications for chemotherapy and targeted therapy: cardiovascular and cerebrovascular diseases; liver and kidney function deficiency; hematological system diseases; clinician consider the patients are not suitable for chemotherapies or target therapies; * Have other malignant tumor previously; * Have surgical contraindications: anesthesia taboo; surgery unresectable extensive lesions; * State of health can't finish the study; * Patient already enrolled in another clinical trial with another anti-cancer therapy or plan to participate in other clinical study. * No self-determination or refuse to participant. * With unlisted exclusion criteria but are considered not suitable for the clinical study by researchers.